Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Beclometason/Formoterol (ATC R03AK08)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline May 31, 2027 · 276 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Beclometason/Formoterol (ATC-Code nach WHO: R03AK08)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

The actual demand is unknown and depends on numerous factors. No minimum order quantities are guaranteed, leading to po...

The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded. In such...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Agreement to provide Beclometason/Formoterol drugs (except 100µg/6µg aerosol) at a discounted price based on the negotiated discount terms.
  • Supply to AOK PLUS insured members in Saxony and Thuringia.
Afficher le résumé complet

This notice is for a non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs.8 SGB V for the active ingredient Beclometason/Formoterol (ATC R03AK08), excluding the 100µg/6µg dosage aerosol. It is an open-house model open to all qualified pharmaceutical companies. No estimated value or guaranteed volume is provided. The agreement ends by 31 May 2027.

Risques

The actual demand is unknown and depends on numerous factors. No minimum order quantities are guaranteed, leading to po...

The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded. In such...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG.

Administrative

  • Must submit participation documents via the DTVP portal (electronic submission required, but not via the standard bidder tool due to open-house nature).
  • Must maintain absolute confidentiality of the participation documents and discount agreement terms.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Beclometason/Formoterol (ATC R03AK08)

Open-house model for a non-exclusive discount agreement on Beclometason/Formoterol products (excluding 100µg/6µg aerosol). No guaranteed volume. Agreement ends 31 May 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2026 - May 2027

Catégorie

Pharmaceutical products

Détails de la procédure

Date de publication
12 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
176734-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30